Literature DB >> 16874533

[Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus].

S Ständer1, H W Reinhardt, T A Luger.   

Abstract

BACKGROUND: Chronic, therapy-resistant pruritus often fails to respond to standard measures so new therapeutic approaches are needed. Recently, the expression of cannabinoid receptors on cutaneous sensory nerve fibers was described, so cannabinoid agonists seem a rational therapeutic option for pruritus. PATIENTS: In an open application observation 22 patients with prurigo, lichen simplex and pruritus applied an emollient cream containing N-palmitoyl ethanolamine (PEA).
RESULTS: In 14/22 patients a good antipruritic effect could be documented. The average reduction in itch was 86.4%. The therapy was well-tolerated by all patients; neither burning burn nor contact dermatitis was observed.
CONCLUSIONS: Topical cannabinoid agonists represent an new effective and well-tolerated therapy for refractory itching of various origins. Creams with a higher concentration may be even more effective with broader indications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16874533     DOI: 10.1007/s00105-006-1180-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  17 in total

1.  Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin.

Authors:  Sonja Ständer; Martin Schmelz; Dieter Metze; Thomas Luger; Roman Rukwied
Journal:  J Dermatol Sci       Date:  2005-06       Impact factor: 4.563

2.  Cannabinoid agonists attenuate capsaicin-induced responses in human skin.

Authors:  Roman Rukwied; Allan Watkinson; Francis McGlone; Melita Dvorak
Journal:  Pain       Date:  2003-04       Impact factor: 6.961

3.  Determination and characterization of a cannabinoid receptor in rat brain.

Authors:  W A Devane; F A Dysarz; M R Johnson; L S Melvin; A C Howlett
Journal:  Mol Pharmacol       Date:  1988-11       Impact factor: 4.436

4.  2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice.

Authors:  R Gallily; A Breuer; R Mechoulam
Journal:  Eur J Pharmacol       Date:  2000-10-06       Impact factor: 4.432

5.  Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed.

Authors:  V Ralevic; D A Kendall
Journal:  Eur J Pharmacol       Date:  2001-04-20       Impact factor: 4.432

Review 6.  The palmitoylethanolamide family: a new class of anti-inflammatory agents?

Authors:  Didier M Lambert; Severine Vandevoorde; Kent-Olov Jonsson; Christopher J Fowler
Journal:  Curr Med Chem       Date:  2002-03       Impact factor: 4.530

Review 7.  Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.

Authors:  V Di Marzo; T Bisogno; L De Petrocellis; D Melck; B R Martin
Journal:  Curr Med Chem       Date:  1999-08       Impact factor: 4.530

8.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

9.  Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.

Authors:  Andis Klegeris; Christopher J Bissonnette; Patrick L McGeer
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

10.  Cannabinoid-receptor expression in human leukocytes.

Authors:  M Bouaboula; M Rinaldi; P Carayon; C Carillon; B Delpech; D Shire; G Le Fur; P Casellas
Journal:  Eur J Biochem       Date:  1993-05-15
View more
  24 in total

1.  [Dermatology seminar Derma Update: extensive CME in 2 days].

Authors:  U Ayazpoor
Journal:  Hautarzt       Date:  2008-02       Impact factor: 0.751

Review 2.  Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?

Authors:  Nicholas K Mollanazar; Peter K Smith; Gil Yosipovitch
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

3.  Chronic pruritus: clinics and treatment.

Authors:  Sonja Grundmann; Sonja Ständer
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

Review 4.  [Topical therapy of inflammatory dermatoses, pruritus and pain, as well as hyperhidrosis].

Authors:  K Schultheis; A Messerschmidt; F Ochsendorf
Journal:  Hautarzt       Date:  2014-03       Impact factor: 0.751

Review 5.  Topical therapies for pruritus.

Authors:  Sarina B Elmariah; Ethan A Lerner
Journal:  Semin Cutan Med Surg       Date:  2011-06

Review 6.  Therapy of pruritus.

Authors:  Tejesh Patel; Gil Yosipovitch
Journal:  Expert Opin Pharmacother       Date:  2010-07       Impact factor: 3.889

Review 7.  Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases.

Authors:  Amber Cintosun; Irene Lara-Corrales; Elena Pope
Journal:  Clin Drug Investig       Date:  2020-04       Impact factor: 2.859

Review 8.  The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.

Authors:  Tamás Bíró; Balázs I Tóth; György Haskó; Ralf Paus; Pál Pacher
Journal:  Trends Pharmacol Sci       Date:  2009-07-14       Impact factor: 14.819

9.  Are itch and scratching the nausea and vomiting of skin?

Authors:  Sattar Ostadhadi; Ehsan Azimi; Ethan A Lerner; Ahmad-Reza Dehpour
Journal:  Exp Dermatol       Date:  2016-02-26       Impact factor: 3.960

Review 10.  Pathogenesis and treatment of pruritus in cholestasis.

Authors:  Andreas E Kremer; Ulrich Beuers; Ronald P J Oude-Elferink; Thomas Pusl
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.